A race for a better Duchenne treatment
On Friday, Pfizer presented the first results in humans for gene therapy to treat Duchenne muscular dystrophy. Pfizer's shares were flat on the announcement, but shares in Sarepta Therapeutics, which develop their own treatment, increased 18%. STAT's senior authors Adam Feuerstein and Matthew Herper sat down with some high-caffeinated drinks this morning to discuss the results.
Adam : Hi, Matt, it looks like Sarepta Therapeutics has a more effective and safer gene therapy than Pfizer. It's the big takeaway from the Pfizer presentation on Friday. How do you feel about it?